421 related articles for article (PubMed ID: 20920995)
1. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
2. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Chu E; Shi N; Wei W; Bendell JC; Cartwright T
Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Chu E; Schulman KL; Zelt S; Song X
Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
6. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
8. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
10. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
13. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
[TBL] [Abstract][Full Text] [Related]
19. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
20. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]